Journal of Antimicrobial Chemotherapy (2000) 45, 797-802
© 2000 The British Society for Antimicrobial Chemotherapy
Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors
Laboratoire de Microbiologie, CHU de la côte de Nacre, Service de Microbiologie, Avenue de la côte de Nacre, 14033 Caen Cedex, France
Linezolid belongs to a new class of antimicrobials, the oxazolidinones, that act by inhibiting protein synthesis. To detect cross-resistance with other inhibitors of protein synthesis (chloramphenicol, macrolides, lincosamides, streptogramins, aminoglycosides and tetracyclines), the in vitro activity of linezolid was determined against isolates harbouring known genes conferring resistance to these antimicrobials. Neither the presence of modifying enzymes (LinA, LinA', LinB, Vgb, Vat, SatA, ANT(4') (4'')-I, AAC(6')-APH(2''), APHA-3 and Cat), nor the presence of an efflux mechanism (MsrA, MefE, MefA, MreA, Vga, TetK and TeL), nor the modification or protection of antimicrobial target (because of ribosomal methylases or TetM and TetO) affected linezolid activity as demonstrated by similar in vitro activity against resistant isolates and sensitive control isolates.
* Corresponding author. Tel: +33-2-31-06-45-72; Fax: +33-2-31-06-45-73; E-mail: leclercq-r{at}chu-caen.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Besier, A. Ludwig, J. Zander, V. Brade, and T. A. Wichelhaus Linezolid Resistance in Staphylococcus aureus: Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1570 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Daeschlein, C. Hoehne, O. Assadian, F. Daxboeck, C. Meinl, A. Kramer, and A.S. Kekule In vitro activity of linezolid against clinical isolates of Fusobacterium spp. J. Antimicrob. Chemother., October 1, 2006; 58(4): 789 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Long, J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2500 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and the Linezolid CSSTI Study Group Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2260 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Curtin, M. Cormican, G. Fleming, J. Keelehan, and E. Colleran Linezolid Compared with Eperezolid, Vancomycin, and Gentamicin in an In Vitro Model of Antimicrobial Lock Therapy for Staphylococcus epidermidis Central Venous Catheter-Related Biofilm Infections Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3145 - 3148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Smith, M. C. Birmingham, G. A. Noskin, A. K. Meagher, A. Forrest, C. R. Rayner, and J. J. Schentag Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia Ann. Onc., May 1, 2003; 14(5): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Novais, J. C. Sousa, T. M. Coque, L. V. Peixe, and the Resistance Study Group First report of the activity of linezolid against Portuguese enterococci from human, animal and environmental sources J. Antimicrob. Chemother., May 1, 2003; 51(5): 1314 - 1315. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bell, J. D. Turnidge, C. H. Ballow, R. N. Jones, and the ZAPS Regional Participants Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific J. Antimicrob. Chemother., February 1, 2003; 51(2): 339 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Baum, S. A. Crawford, M. L. McElmeel, C. G. Whitney, and J. H. Jorgensen Comparative Activities of the Oxazolidinone AZD2563 and Linezolid against Selected Recent North American Isolates of Streptococcus pneumoniae Antimicrob. Agents Chemother., September 1, 2002; 46(9): 3094 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gentry-Nielsen, K. M. Olsen, and L. C. Preheim Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1345 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Conte Jr., J. A. Golden, J. Kipps, and E. Zurlinden Intrapulmonary Pharmacokinetics of Linezolid Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1475 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Dailey, C. L. Dileto-Fang, L. V. Buchanan, M. P. Oramas-Shirey, D. H. Batts, C. W. Ford, and J. K. Gibson Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2304 - 2308. [Abstract] [Full Text] [PDF]
|
|